Flow cytometry is considered an ideal technology for the detection of rare populations of cells.
TORONTO (PRWEB)
March 15, 2023
Rare event analysis by flow cytometry is relatively common in research settings, in clinical laboratories and during drug discovery and development. For example, in research and drug discovery environments, the measurement of intracellular cytokines and intracellular signaling events (i.e., protein phosphorylation) are some of the more common rare event assays. Whereas in clinical laboratories, assays for rare events often include the measurement of CD34+ hematopoietic stem cells, paroxysmal nocturnal hemoglobinuria (PNH) and minimal residual disease (MRD) of blood cancers. During drug development and clinical trial evaluation of new therapeutic modalities, rare event methods might also include the monitoring of CAR cellular therapies and the efficacy of cell-depleting therapies.
Flow cytometry is considered an ideal technology for the detection of rare populations of cells. Not only can multiple characteristics on individual cells be measured, but also a large number of cells can be evaluated in a relatively short amount of time. However, as the technology moves out of research and non-regulated settings into clinical laboratories and the regulated phases of preclinical and clinical drug development, concerns related to how to develop, validate and implement robust assays for rare event measurements arise.
This webinar will address those concerns by introducing the concept Design Control and how its application can facilitate assay development and validation. Design Control is a structured process which is applied to the conduct of product development activities. While Design Control is mandatory in regulated industries, it can be easily adopted in non-regulated settings to increase successful outcomes.
Register today and learn about rare event analysis in flow cytometry using design control and validation approaches aligned with CLSI H62.
Join Virginia Litwin, PhD, Director of Scientific Affairs, Eurofins BioPharma Services, for the live webinar on Wednesday, April 5, 2023, at 11am EDT (5pm CEST/EU-Central).
For more information, or to register for this event, visit Rare Event Analysis in Flow Cytometry: Design Control and Validation Aligned with CLSI H62.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: